The developer company reported the death of a Russian child during treatment with Zolgensma
[ad_1]
Two children from Russia and Kazakhstan died while being treated for spinal muscular atrophy (SMA) with Zolgensma. This was announced by its developer, the Swiss pharmaceutical company Novartis.
“Zolgensma” is considered the most expensive drug in the world. One dose of it is enough to save the patient’s life, but its cost exceeds $2 million.
Novartis claims that the cause of death was acute liver failure. The children died after five to six weeks of Zolgensma and 1 to 10 days after gradually tapering the dose of corticosteroids (hormones given to reduce inflammation), the company said in a statement, which cites Reuters. Names, ages and other details about the condition of the dead are not given.
Zolgensma was registered in Russia in December 2021. Officially drug introduced into civil circulation in the country in July 2022. Since the beginning of the year, Zolgensma has received at least five children: one-year-old Victoria Snegireva from Severodvinsk, Michel Proshchenko and Vanya Kotov , Vova Sologub, Mark Ugrekhelidze (all four are from the Krasnodar Territory).
Chief geneticist of Russia Sergey Kutsev arguedthat “Zolgensma” is not well understood. Head of FMBA Veronika Skvortsova assuredthat in Russia they will “easily” cope with the creation of an analogue of this medicine. Start analog production are planning in Kazan in 2025.
About the problems with the purchases of “Zolgensma” – in the material “Kommersant” “Children with SMA are not in circulation”.
[ad_2]
Source link
